Business Description
Rocket Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US77313F1066
Description
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.19 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7.4 | |||||
| 3-Year EPS without NRI Growth Rate | -5 | |||||
| 3-Year FCF Growth Rate | -10.4 | |||||
| 3-Year Book Growth Rate | -12.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 22.08 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.99 | |||||
| 9-Day RSI | 25.37 | |||||
| 14-Day RSI | 28.11 | |||||
| 6-1 Month Momentum % | -37.23 | |||||
| 12-1 Month Momentum % | -53.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.05 | |||||
| Quick Ratio | 6.05 | |||||
| Cash Ratio | 5.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14 | |||||
| Shareholder Yield % | -0.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -58.93 | |||||
| ROA % | -51.52 | |||||
| ROIC % | -160.27 | |||||
| ROC (Joel Greenblatt) % | -294.71 | |||||
| ROCE % | -55.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.16 | |||||
| Price-to-Tangible-Book | 3.93 | |||||
| EV-to-EBIT | -3.99 | |||||
| EV-to-Forward-EBIT | -3.41 | |||||
| EV-to-EBITDA | -4.13 | |||||
| EV-to-Forward-EBITDA | -3.46 | |||||
| EV-to-Forward-Revenue | 105.34 | |||||
| EV-to-FCF | -5.05 | |||||
| Price-to-Net-Current-Asset-Value | 6.05 | |||||
| Price-to-Net-Cash | 6.28 | |||||
| Earnings Yield (Greenblatt) % | -25.06 | |||||
| FCF Yield % | -16.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RCKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rocket Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.75 | ||
| Beta | 0.63 | ||
| Volatility % | 48.05 | ||
| 14-Day RSI | 28.11 | ||
| 14-Day ATR ($) | 0.796054 | ||
| 20-Day SMA ($) | 13.0295 | ||
| 12-1 Month Momentum % | -53.12 | ||
| 52-Week Range ($) | 11.15 - 32.525 | ||
| Shares Outstanding (Mil) | 106.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rocket Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rocket Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rocket Pharmaceuticals Inc Frequently Asked Questions
What is Rocket Pharmaceuticals Inc(RCKT)'s stock price today?
The current price of RCKT is $11.77. The 52 week high of RCKT is $32.53 and 52 week low is $11.15.
When is next earnings date of Rocket Pharmaceuticals Inc(RCKT)?
The next earnings date of Rocket Pharmaceuticals Inc(RCKT) is 2025-02-26 Est..
Does Rocket Pharmaceuticals Inc(RCKT) pay dividends? If so, how much?
Rocket Pharmaceuticals Inc(RCKT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers